Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Value of Tissue Vascular Endothelial Growth Factor Expression in Bladder Cancer: a Meta-analysis

  • Huang, Yu-Jing (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University) ;
  • Qi, Wei-Xiang (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University) ;
  • He, Ai-Na (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University) ;
  • Sun, Yuan-Jue (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University) ;
  • Shen, Zan (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University) ;
  • Yao, Yang (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University)
  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The prognostic role of vascular endothelial growth factor (VEGF) in bladder cancer remains controversial. This meta-analysis aimed to explore any association between overexpression and survival outcomes. Methods: We systematically searched for studies investigating the relationships between VEGF expression and outcome of bladder cancer patients. Study quality was assessed using the Newcastle-Ottawa Scale. After careful review, survival data were extracted from eligible studies. A meta-analysis was performed to generate combined hazard ratios (HRs) for overall survival (OS), disease-free survival (DFS) and disease-specific survival (DSS). Results: A total of 1,285 patients from 11 studies were included in the analysis. Our results showed that tissue VEGF overexpression in patients with bladder cancer was associated with poor prognosis in terms of OS (HR, 1.843; 95% CI, 1.231-2.759; P = 0.003), DFS (HR, 1.498; 95% CI, 1.255-1.787; P = 0.000) and DSS (HR, 1.562; 95% CI, 0.996-1.00; P = 0.052), though the difference for DSS was not statistically significant. In addition, there was no evidence of publication bias as suggested by Begg's and Egger's tests except for DFS (Begg's test, P = 0.221; Egger's test, P = 0.018). Conclusion: The present meta-analysis indicated elevated VEGF expression to be associated with a poor prognosis in patients with bladder cancer.

Keywords

References

  1. Bernardini S, Fauconnet S, Chabannes E, et al (2001). Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol, 166, 1275-9. https://doi.org/10.1016/S0022-5347(05)65752-7
  2. Chen J, Li T, Wu Y, et al (2011). Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J Cancer Res Clin Oncol, 137, 1799-812. https://doi.org/10.1007/s00432-011-1057-2
  3. Crew JP, O'Brien T, Bradburn M, et al (1997). Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res, 57, 5281-5.
  4. DerSimonian Rand Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  5. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  6. Ferrara N (2004). Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev, 25, 581-611. https://doi.org/10.1210/er.2003-0027
  7. Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1, 27-31. https://doi.org/10.1038/nm0195-27
  8. Hanahan Dand Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74. https://doi.org/10.1016/j.cell.2011.02.013
  9. Herrmann E, Eltze E, Bierer S, et al (2007). VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival. Anticancer Res, 27, 3127-33.
  10. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  11. Inoue K, Slaton JW, Karashima T, et al (2000). The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res, 6, 4866-73.
  12. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  13. Kanda S, Miyata Y and Kanetake H (2006). Current status and perspective of antiangiogenic therapy for cancer: urinary cancer. Int J Clin Oncol, 11, 90-107. https://doi.org/10.1007/s10147-006-0565-6
  14. Li Z, Qi F, Qi L, et al (2011). VEGF-C as a decision-making biomarker for selected patients with invasive bladder cancer who underwent bladder-preserving radical surgery. Arch Med Res, 42, 405-11. https://doi.org/10.1016/j.arcmed.2011.07.006
  15. Ma Y, Hou Y, Liu B, et al (2010). Intratumoral lymphatics and lymphatic vessel invasion detected by D2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma. Anat Rec (Hoboken), 293, 1847-54. https://doi.org/10.1002/ar.21217
  16. Nadaoka J, Horikawa Y, Saito M, et al (2008). Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder. Int J Cancer, 122, 1297-302.
  17. Parmar MK, Torri V and Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  18. Pignot G, Bieche I, Vacher S, et al (2009). Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. Eur Urol, 56, 678-88. https://doi.org/10.1016/j.eururo.2008.05.027
  19. Qu JT, Wang M, He HL, et al (2012). The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review. J Cancer Res Clin Oncol, 138, 819-25. https://doi.org/10.1007/s00432-012-1149-7
  20. Schoenleber SJ, Kurtz DM, Talwalkar JA, et al (2009). Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer, 100, 1385-92. https://doi.org/10.1038/sj.bjc.6605017
  21. Shariat SF, Youssef RF, Gupta A, et al (2010). Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol, 183, 1744-50. https://doi.org/10.1016/j.juro.2010.01.018
  22. Suzuki K, Morita T and Tokue A (2005). Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int J Urol, 12, 152-8. https://doi.org/10.1111/j.1442-2042.2005.01010.x
  23. Szarvas T, Jager T, Droste F, et al (2009). Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. Pathol Oncol Res, 15, 193-201. https://doi.org/10.1007/s12253-008-9107-z
  24. Szarvas T, Jager T, Totsch M, et al (2008). Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer. Clin Cancer Res, 14, 8253-62. https://doi.org/10.1158/1078-0432.CCR-08-0677
  25. Theodoropoulos VE, Lazaris A, Sofras F, et al (2004). Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol, 46, 200-8. https://doi.org/10.1016/j.eururo.2004.04.008
  26. Thieblemont C, Fendler JP, Trillet-Lenoir V, et al (1996). [Prognostic factors of survival in infiltrating urothelial bladder carcinoma. A retrospective study of 158 patients treated by radical cystectomy]. Bull Cancer, 83, 139-46.
  27. van Rhijn BW (2012). Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer. Urol Oncol, 30, 518-23. https://doi.org/10.1016/j.urolonc.2012.04.002
  28. Wells GA, Brodsky L, O'Connell D, et al (2003). An Evaluation of the Newcastle Ottawa Scale: An Assessment Tool for Evaluating the Quality of Non-Randomized Studies. In XI Cochrane Colloquium Vol. O-63. p 26. Barcelona: XI International Cochrane Colloquium Book of Abstracts.
  29. Yang CC, Chu KC and Yeh WM (2004). The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol, 22, 1-6. https://doi.org/10.1016/S1078-1439(03)00015-2
  30. Youssef RFand Lotan Y (2011). Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. ScientificWorldJournal, 11, 369-81. https://doi.org/10.1100/tsw.2011.28
  31. Yu L, Deng L, Li J, et al (2012). The prognostic value of vascular endothelial growth factor in ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol, 128, 391-6.
  32. Zaravinos A, Volanis D, Lambrou GI, et al (2012). Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder. Oncol Rep, 28, 1159-66.
  33. Zhan P, Wang J, Lv XJ, et al (2009). Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol, 4, 1094-103. https://doi.org/10.1097/JTO.0b013e3181a97e31
  34. Zu X, Tang Z, Li Y, et al (2006). Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int, 98, 1090-3. https://doi.org/10.1111/j.1464-410X.2006.06446.x

Cited by

  1. Serum Vascular Endothelial Growth Factor-A (VEGF-A) as a Biomarker in Squamous Cell Carcinoma of Head and Neck Patients Undergoing Chemoradiotherapy vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3261
  2. Therapeutic Implications of Black Seed and Its Constituent Thymoquinone in the Prevention of Cancer through Inactivation and Activation of Molecular Pathways vol.2014, pp.1741-4288, 2014, https://doi.org/10.1155/2014/724658
  3. Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies vol.15, pp.1, 2015, https://doi.org/10.1186/s12885-015-1524-2
  4. Can Recurrence and Progression be Predicted by HYAL-1 Expression in Primary T1 Bladder Cancer? vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10401
  5. Expression of Aquaporin 1 in Bladder Uroepithelial Cell Carcinoma and its Relevance to Recurrence vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3973
  6. Prognostic Factors in Urothelial Carcinoma of the Bladder vol.22, pp.2, 2015, https://doi.org/10.1097/PAP.0000000000000050
  7. Workplace Accommodation Among Persons with Disabilities: A Systematic Review of Its Effectiveness and Barriers or Facilitators vol.25, pp.2, 2015, https://doi.org/10.1007/s10926-014-9548-z
  8. Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients vol.22, pp.2, 2017, https://doi.org/10.1080/1354750X.2016.1252955
  9. MicroRNA-302a inhibits cell proliferation and invasion, and induces cell apoptosis in hepatocellular carcinoma by directly targeting VEGFA vol.16, pp.5, 2017, https://doi.org/10.3892/mmr.2017.7312
  10. A Meta-Analysis of Vascular Endothelial Growth Factor for Nasopharyngeal Cancer Prognosis vol.8, pp.2234-943X, 2018, https://doi.org/10.3389/fonc.2018.00486